Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment

[1]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[2]  T. Klingebiel,et al.  Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting , 1998, Bone Marrow Transplantation.

[3]  S. Mackinnon,et al.  T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. , 1998, Blood.

[4]  M. Stimpfl,et al.  Quantification of CD34+ cells: comparison of methods , 1997, Transfusion.

[5]  N. Schmitz,et al.  Allogeneic blood stem cell transplantation: considerations for donors. , 1997, Blood.

[6]  M. Bishop,et al.  Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. , 1996, Bone marrow transplantation.

[7]  G. Hale,et al.  Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission , 1996, British journal of haematology.

[8]  M. Trigg,et al.  Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. , 1996, Blood.

[9]  M. Okada,et al.  Second transplantation with CD34+ bone marrow cells selected from a two‐loci HLA‐mismatched sibling for a patient with chronic myeloid leukaemia , 1996, British journal of haematology.

[10]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[11]  P. Henslee-Downey,et al.  Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: clinical and immunologic characteristics. , 1996, Bone marrow transplantation.

[12]  M. Bishop,et al.  Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. , 1996, Bone marrow transplantation.

[13]  E. Romond,et al.  Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. , 1996, Transplantation.

[14]  R. Storb,et al.  Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor , 1996, Stem cells.

[15]  Y. Reisner,et al.  Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice , 1995, Nature Medicine.

[16]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[17]  Giralt,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.

[18]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[19]  Y. Ravindranath,et al.  Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. , 1994, Bone marrow transplantation.

[20]  F. Lacombe,et al.  Cytokine-mediated expansion of 5-FU resistant peripheral blood stem cells and bone marrow: self-renewal and commitment capacity. , 1994, Journal of hematotherapy.

[21]  H. Heimpel,et al.  Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation. , 1993, Leukemia.

[22]  M. Martelli,et al.  Enhancement of T cell-depleted bone marrow allografts in mice by thiotepa. , 1990, Transplantation.

[23]  P. Colombat,et al.  Cutaneous toxicity of autologous bone marrow transplantation in nonseminomatous germ cell tumors , 1990, Cancer.

[24]  Brenda,et al.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. , 1989, Blood.

[25]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Burke,et al.  Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. , 1988, Blood.

[27]  G. Hale,et al.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.

[28]  B. Dupont,et al.  Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. , 1983, Blood.

[29]  M. O'Leary,et al.  An improved method for T-cell depletion of allogeneic histoincompatible donor bone marrow. , 1983, Cancer drug delivery.